Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07814664) titled 'Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: Chinese SLE Treatment And Research Group

Condition: Systemic Lupus Erthematosus

Intervention: Drug: Ivarmacitinib Sulfate Tablets

Recruitment Status: Not recruiting

Phase: Phase 2/Phase 3

Date of First Enrollment: October 15, 2026

Target Sample Size: 294

Countries of Recruitment: China

To kno...